Adamax Legal to Purchase for Research? (Legality Explained)

A 2019 WADA bulletin listed SR9009 (marketed variously as Adamax, Stenabolic, or REV-ERB agonist formulations) as a prohibited substance for athletes. Yet the compound remains legally available for purchase as a research chemical. The regulatory disconnect isn't an oversight. SR9009 was never approved as a drug, never classified as a controlled substance under the DEA scheduling system, and exists in a category the FDA calls 'investigational new drugs'. Compounds that can be sold for laboratory research but not for human consumption. Our team has guided dozens of research institutions through procurement compliance for REV-ERB agonists. The legal line is sharper than most suppliers acknowledge.

Is Adamax legal to purchase for research purposes?

Yes. SR9009 (sold under brand names including Adamax) is legal to purchase for in-vitro research in the absence of an intent to use it in human subjects. The compound is not scheduled under the Controlled Substances Act, not approved by the FDA for therapeutic use, and exists in regulatory limbo as an investigational compound. Researchers can legally acquire it from chemical suppliers for laboratory studies, provided the purchase is documented as research-only and not intended for human or animal administration outside an approved clinical trial framework. The FDA has not issued enforcement actions against suppliers selling SR9009 for research. The enforcement focus remains on vendors marketing it as a dietary supplement or performance enhancer for human use.

Here's what most procurement guides miss: the legality of purchasing Adamax for research depends entirely on intended use documentation. A supplier selling '99% pure SR9009 for laboratory research' operates within current regulatory boundaries. The same supplier selling 'Adamax for bodybuilding' or 'REV-ERB agonist for fat loss' crosses into FDA enforcement territory under the Federal Food, Drug, and Cosmetic Act. This article covers the actual regulatory framework governing SR9009 purchase, what separates compliant research procurement from illegal human-use marketing, and the compliance documentation required to purchase REV-ERB agonists without institutional risk.

What SR9009 (Adamax) Actually Is — and Why the Name Matters

SR9009 is a synthetic REV-ERB agonist developed at The Scripps Research Institute in 2012 as a tool compound for studying circadian rhythm regulation and metabolic pathways. REV-ERBα and REV-ERBβ are nuclear receptors that regulate the expression of genes involved in lipid metabolism, mitochondrial biogenesis, and glucose homeostasis. SR9009 binds to these receptors and modulates their transcriptional activity. The compound was never intended as a therapeutic drug. It was designed as a research probe to understand how circadian clock proteins influence metabolism, published in Nature Medicine in a 2012 study demonstrating increased exercise capacity and altered lipid profiles in mouse models.

The brand name 'Adamax' is a supplier designation, not a chemical name. Multiple vendors market SR9009 under proprietary labels. Stenabolic, REV-ERB, Metabolic Modulator. To differentiate their formulations in the research chemical market. This naming convention creates confusion: researchers searching for 'is Adamax legal' are asking about a brand, not the underlying molecule. The legal status of SR9009 itself is unambiguous. It's an unscheduled research chemical. What varies is how it's marketed. A Certificate of Analysis (CoA) listing 'SR9009, CAS 1379686-30-2, ≥99% purity by HPLC' describes a compliant research product. A label reading 'Adamax. Burn Fat, Increase Endurance' describes an unapproved drug being marketed illegally for human use.

The Regulatory Framework Governing Research Chemical Purchases

The FDA does not pre-approve the sale of investigational compounds for laboratory research. That authority falls under the Federal Food, Drug, and Cosmetic Act's provisions for 'investigational new drugs' (INDs), which apply when a compound is used in clinical trials involving human subjects. For in-vitro or animal model research conducted outside an IND application, the compound remains unregulated at the point of sale. The DEA's Controlled Substances Act schedules drugs based on abuse potential and accepted medical use. SR9009 meets neither criterion for scheduling. It has no accepted medical use (because it was never approved) and no established abuse liability (because there's minimal human use data). As of 2026, SR9009 remains unscheduled.

What does regulate SR9009 purchase is institutional compliance policy. Research institutions purchasing chemicals for laboratory use must maintain Material Safety Data Sheets (MSDS), document intended use in grant applications or internal research protocols, and ensure chemical handling complies with OSHA and EPA regulations for hazardous materials. A university purchasing SR9009 from Real Peptides for mitochondrial biogenesis studies would document the purchase as 'REV-ERB agonist for in-vitro metabolic pathway analysis' and store it under controlled-access laboratory conditions. The purchase itself is legal. The documentation ensures institutional liability protection if the compound is later misused.

The enforcement boundary the FDA has drawn is marketing intent. In 2017, the agency issued warning letters to supplement companies selling SARMs (selective androgen receptor modulators) and other research chemicals as bodybuilding products. The letters cited violations of the FDCA for marketing unapproved drugs. Not for selling research chemicals. SR9009 falls into this same category. Suppliers marketing it 'for research only' with no therapeutic claims operate outside FDA enforcement scope. Suppliers marketing it for human performance enhancement trigger enforcement action.

Comparison: Research Chemical Legality Across Compound Classes

Key Takeaways

• SR9009 (marketed as Adamax, Stenabolic, or REV-ERB agonist) is legal to purchase for in-vitro research because it remains unscheduled under the Controlled Substances Act and unapproved by the FDA.
• The compound exists in regulatory limbo as an 'investigational new drug'. It can be sold for laboratory research but not marketed for human consumption without triggering FDA enforcement.
• Institutional compliance requires documenting purchase intent as research-only, maintaining Material Safety Data Sheets, and storing compounds under controlled-access laboratory conditions.
• The FDA's enforcement focus is on marketing claims, not the sale of research chemicals. Suppliers marketing SR9009 'for bodybuilding' or 'fat loss' violate the Federal Food, Drug, and Cosmetic Act.
• SR9009 was developed at The Scripps Research Institute as a tool compound for studying circadian rhythm regulation, not as a therapeutic agent. Its legal status reflects its origin as a research probe.
• WADA banned SR9009 for athletic use in 2019, but this prohibition applies only to competitive sports, not to laboratory research procurement.

What If: Adamax Legal to Purchase for Research Scenarios

What If My Institution's Compliance Office Flags SR9009 as a 'Controlled Substance'?

Provide the DEA's current Controlled Substances List (updated quarterly on the DEA Diversion Control Division website) showing SR9009 is not scheduled. The confusion typically stems from conflating 'research chemical' with 'controlled substance'. The terms are not synonymous. Controlled substances are explicitly listed in Schedules I–V under 21 U.S.C. § 812, and SR9009 appears on none of them. If your compliance officer insists it's controlled, request the specific CFR citation or DEA Orange Book entry. They won't find one because it doesn't exist. What may trigger flags is institutional policy on 'compounds with abuse potential'. Some universities restrict procurement of any compound that could theoretically be misused, regardless of scheduling status.

What If a Supplier Refuses to Sell SR9009 Without an Institutional Purchase Order?

This is standard practice for reputable chemical suppliers and actually signals compliance-focused operations. Companies like Real Peptides require institutional documentation (PO number, lab contact, research protocol summary) to ensure the purchase is legitimate research procurement, not individual human use. If you're an independent researcher without institutional affiliation, procurement becomes significantly more complex. Most suppliers will not sell research chemicals to individuals because the liability risk is too high. The workaround is collaborating with an accredited research institution that can issue the purchase order, or working through a CRO (contract research organization) that holds the necessary credentials.

What If I Purchase SR9009 for Research but Later Want to Use It in a Human Clinical Trial?

You cannot legally transition a research chemical purchase into human use without filing an Investigational New Drug (IND) application with the FDA and receiving approval to proceed. The IND process requires preclinical toxicology data, manufacturing controls documentation (GMP compliance), a clinical protocol reviewed by an IRB, and informed consent procedures. Simply purchasing SR9009 from a research supplier does not grant authority to administer it to human subjects. Doing so without an approved IND is a federal crime under 21 U.S.C. § 355. If your research suggests SR9009 has therapeutic potential, the regulatory pathway is: complete in-vitro and animal studies, file a pre-IND meeting request with the FDA, compile the required safety data, then submit the IND before any human administration occurs.

The Unvarnished Truth About SR9009 Research Legality

Here's the honest answer: purchasing SR9009 for research is legal, but the industry built around it is deliberately opaque. Suppliers use brand names like Adamax to obscure the fact that they're selling an investigational compound with zero human safety data, and researchers. Particularly those in performance science or anti-aging fields. Sometimes purchase these compounds with a wink-and-nod understanding that 'research' means self-experimentation. That's not legal. It's not compliant. And it's the exact behavior that eventually triggers FDA enforcement actions that shut down legitimate research access.

The FDA has historically taken a light-touch approach to research chemical suppliers because they serve a legitimate function in academic and pharmaceutical R&D. But when suppliers start marketing 'research-grade SR9009' with dosing protocols, cycle lengths, and before-and-after photos. They're no longer selling research chemicals, they're selling unapproved drugs. And when that pattern becomes widespread, the FDA steps in. We saw this with SARMs in 2017, with peptides in 2020, and we're likely to see it with REV-ERB agonists if the current marketing trajectory continues. If you're a genuine researcher, document everything. If you're not. Understand that purchasing a 'research chemical' for personal use doesn't make it legal just because the website says 'not for human consumption.'

Why REV-ERB Agonists Remain Unscheduled Despite Athletic Bans

WADA's 2019 prohibition of SR9009 under Section S4 (Hormone and Metabolic Modulators) applies exclusively to competitive athletes under the World Anti-Doping Code. It carries no legal force outside the sports governance context. Athletes who test positive for SR9009 face suspension, but the compound itself is not illegal to possess or purchase. This is identical to the regulatory status of compounds like meldonium or GW501516. Banned in sports, unscheduled by the DEA, and legally available for research.

The DEA schedules substances based on abuse potential, accepted medical use, and safety profile. SR9009 has no established abuse liability because human use data is essentially non-existent. The 2012 Scripps study used mouse models, and no Phase I safety trial has ever been published. Without human pharmacokinetic data, the DEA has no basis to schedule it. This is why SR9009 remains legal to purchase while compounds like DMAA (1,3-dimethylamylamine) were eventually scheduled. DMAA had documented human use, adverse event reports, and a pattern of recreational misuse. SR9009 hasn't reached that threshold, and unless widespread human adverse events emerge, it's unlikely to be scheduled in the near term.

Research institutions purchasing REV-ERB agonists should focus on supplier verification rather than legal status. The compound's legality is settled. What varies is supplier reliability. A Certificate of Analysis from an ISO-accredited lab showing ≥98% purity by HPLC with <2% impurities is baseline. Third-party testing, sterility certification for injectable formulations, and transparent chain-of-custody documentation separate compliant suppliers from grey-market operators. We recommend cross-referencing supplier claims with independent analytical chemistry labs. Send a blinded sample to a university lab for verification before committing to large-volume procurement. The molecule is legal. The supplier might not be trustworthy.

The regulatory gap around SR9009 isn't permanent. It's conditional on the compound remaining a niche research tool rather than becoming a mass-market consumer product. If marketing trends shift and REV-ERB agonists start appearing in mainstream supplement formulations, expect FDA enforcement actions followed by potential DEA scheduling. Until then, institutional researchers have clear legal authority to purchase SR9009 for in-vitro and animal model studies, provided procurement is documented, stored appropriately, and never marketed or administered for human use outside an approved clinical trial framework.